Effects	effects	O	O	O	O
of	of	O	O	O	O
long-term	long-term	O	O	O	O
pretreatment	pretreatment	O	O	O	O
with	with	O	O	O	O
isoproterenol	isoproterenol	CHEMICALS	O	OTHERS	I
on	on	O	O	O	O
bromocriptine-induced	bromocriptine-induced	O	O	O	O
tachycardia	tachycardia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
conscious	conscious	O	O	O	O
rats	rats	O	O	O	O
.	.	O	O	O	O

It	it	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
shown	shown	O	O	O	O
that	that	O	O	O	O
bromocriptine-induced	bromocriptine-induced	O	O	O	O
tachycardia	tachycardia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
which	which	O	O	O	O
persisted	persisted	O	O	O	O
after	after	O	O	O	O
adrenalectomy	adrenalectomy	O	O	O	O
,	,	O	O	O	O
is	is	O	O	O	O
(	(	O	O	O	O
i	i	O	O	O	O
)	)	O	O	O	O
mediated	mediated	O	O	O	O
by	by	O	O	O	O
central	central	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
D2	d2	O	O	O	O
receptor	receptor	O	O	O	O
activation	activation	O	O	O	O
and	and	O	O	O	O
(	(	O	O	O	O
ii	ii	O	O	O	O
)	)	O	O	O	O
reduced	reduced	O	O	O	O
by	by	O	O	O	O
5-day	5-day	O	O	O	O
isoproterenol	isoproterenol	CHEMICALS	O	OTHERS	I
pretreatment	pretreatment	O	O	O	O
,	,	O	O	O	O
supporting	supporting	O	O	O	O
therefore	therefore	O	O	O	O
the	the	O	O	O	O
hypothesis	hypothesis	O	O	O	O
that	that	O	O	O	O
this	this	O	O	O	O
effect	effect	O	O	O	O
is	is	O	O	O	O
dependent	dependent	O	O	O	O
on	on	O	O	O	O
sympathetic	sympathetic	O	O	O	O
outflow	outflow	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
heart	heart	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
conducted	conducted	O	O	O	O
to	to	O	O	O	O
examine	examine	O	O	O	O
whether	whether	O	O	O	O
prolonged	prolonged	O	O	O	O
pretreatment	pretreatment	O	O	O	O
with	with	O	O	O	O
isoproterenol	isoproterenol	CHEMICALS	O	OTHERS	I
could	could	O	O	O	O
abolish	abolish	O	O	O	O
bromocriptine-induced	bromocriptine-induced	O	O	O	O
tachycardia	tachycardia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
conscious	conscious	O	O	O	O
rats	rats	O	O	O	O
.	.	O	O	O	O

Isoproterenol	isoproterenol	CHEMICALS	O	OTHERS	I
pretreatment	pretreatment	O	O	O	O
for	for	O	O	O	O
15	15	O	O	O	O
days	days	O	O	O	O
caused	caused	O	O	O	O
cardiac	cardiac	O	DISEASE	OTHERS	I
hypertrophy	hypertrophy	O	DISEASE	OTHERS	I
without	without	O	O	O	O
affecting	affecting	O	O	O	O
baseline	baseline	O	O	O	O
blood	blood	O	O	O	O
pressure	pressure	O	O	O	O
and	and	O	O	O	O
heart	heart	O	O	O	O
rate	rate	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
control	control	O	O	O	O
rats	rats	O	O	O	O
,	,	O	O	O	O
intravenous	intravenous	O	O	O	O
bromocriptine	bromocriptine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
150	150	O	O	O	O
microg/kg	microg/kg	O	O	O	O
)	)	O	O	O	O
induced	induced	O	O	O	O
significant	significant	O	O	O	O
hypotension	hypotension	O	DISEASE	OTHERS	I
and	and	O	O	O	O
tachycardia	tachycardia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Bromocriptine-induced	bromocriptine-induced	O	O	O	O
hypotension	hypotension	O	DISEASE	OTHERS	I
was	was	O	O	O	O
unaffected	unaffected	O	O	O	O
by	by	O	O	O	O
isoproterenol	isoproterenol	CHEMICALS	O	OTHERS	I
pretreatment	pretreatment	O	O	O	O
,	,	O	O	O	O
while	while	O	O	O	O
tachycardia	tachycardia	O	DISEASE	OTHERS	I
was	was	O	O	O	O
reversed	reversed	O	O	O	O
to	to	O	O	O	O
significant	significant	O	O	O	O
bradycardia	bradycardia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
an	an	O	O	O	O
effect	effect	O	O	O	O
that	that	O	O	O	O
was	was	O	O	O	O
partly	partly	O	O	O	O
reduced	reduced	O	O	O	O
by	by	O	O	O	O
i.v	i.v	O	O	O	O
.	.	O	O	O	O

domperidone	domperidone	O	O	OTHERS	I
(	(	O	O	O	O
0.5	0.5	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Neither	neither	O	O	O	O
cardiac	cardiac	O	O	O	O
vagal	vagal	O	O	O	O
nor	nor	O	O	O	O
sympathetic	sympathetic	O	O	O	O
tone	tone	O	O	O	O
was	was	O	O	O	O
altered	altered	O	O	O	O
by	by	O	O	O	O
isoproterenol	isoproterenol	CHEMICALS	O	OTHERS	I
pretreatment	pretreatment	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
isolated	isolated	O	O	O	O
perfused	perfused	O	O	O	O
heart	heart	O	O	O	O
preparations	preparations	O	O	O	O
from	from	O	O	O	O
isoproterenol-pretreated	isoproterenol-pretreated	O	O	O	O
rats	rats	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
isoproterenol-induced	isoproterenol-induced	O	O	O	O
maximal	maximal	O	O	O	O
increase	increase	O	O	O	O
in	in	O	O	O	O
left	left	O	O	O	O
ventricular	ventricular	O	O	O	O
systolic	systolic	O	O	O	O
pressure	pressure	O	O	O	O
was	was	O	O	O	O
significantly	significantly	O	O	O	O
reduced	reduced	O	O	O	O
,	,	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
saline-pretreated	saline-pretreated	O	O	O	O
rats	rats	O	O	O	O
(	(	O	O	O	O
the	the	O	O	O	O
EC50	ec50	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
isoproterenol-induced	isoproterenol-induced	O	O	O	O
increase	increase	O	O	O	O
in	in	O	O	O	O
left	left	O	O	O	O
ventricular	ventricular	O	O	O	O
systolic	systolic	O	O	O	O
pressure	pressure	O	O	O	O
was	was	O	O	O	O
enhanced	enhanced	O	O	O	O
approximately	approximately	O	O	O	O
22-fold	22-fold	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
results	results	O	O	O	O
show	show	O	O	O	O
that	that	O	O	O	O
15-day	15-day	O	O	O	O
isoproterenol	isoproterenol	CHEMICALS	O	OTHERS	I
pretreatment	pretreatment	O	O	O	O
not	not	O	O	O	O
only	only	O	O	O	O
abolished	abolished	O	O	O	O
but	but	O	O	O	O
reversed	reversed	O	O	O	O
bromocriptine-induced	bromocriptine-induced	O	O	O	O
tachycardia	tachycardia	O	DISEASE	OTHERS	I
to	to	O	O	O	O
bradycardia	bradycardia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
an	an	O	O	O	O
effect	effect	O	O	O	O
that	that	O	O	O	O
is	is	O	O	O	O
mainly	mainly	O	O	O	O
related	related	O	O	O	O
to	to	O	O	O	O
further	further	O	O	O	O
cardiac	cardiac	O	O	O	O
beta-adrenoceptor	beta-adrenoceptor	O	O	O	O
desensitization	desensitization	O	O	O	O
rather	rather	O	O	O	O
than	than	O	O	O	O
to	to	O	O	O	O
impairment	impairment	O	O	O	O
of	of	O	O	O	O
autonomic	autonomic	O	O	O	O
regulation	regulation	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
heart	heart	O	O	O	O
.	.	O	O	O	O

They	they	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
normal	normal	O	O	O	O
conscious	conscious	O	O	O	O
rats	rats	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
central	central	O	O	O	O
tachycardia	tachycardia	O	DISEASE	OTHERS	I
of	of	O	O	O	O
bromocriptine	bromocriptine	CHEMICALS	O	OTHERS	I
appears	appears	O	O	O	O
to	to	O	O	O	O
predominate	predominate	O	O	O	O
and	and	O	O	O	O
to	to	O	O	O	O
mask	mask	O	O	O	O
the	the	O	O	O	O
bradycardia	bradycardia	O	DISEASE	OTHERS	I
of	of	O	O	O	O
this	this	O	O	O	O
agonist	agonist	O	O	O	O
at	at	O	O	O	O
peripheral	peripheral	O	O	O	O
dopamine	dopamine	CHEMICALS	O	OTHERS	I
D2	d2	O	O	O	O
receptors	receptors	O	O	O	O
.	.	O	O	O	O

